Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 259-715-3 | CAS number: 55589-62-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 500 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- The quality of the whole data base is considered to be sufficient and not critical.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Acesulfame potassium was investigated for its effect on fertility, reproductive performance, pre- and postnatal development in male and female Wistar rats at dietary levels of 0, 0.3, 1.0 and 3.0% in three successive generations, each comprising two consecutive litters. A teratogenicity study was conducted with 15 females per group of the F2b and F3a generations. Rats from the F3b generation were submitted to clinical and pathological examination. Pups from the F1a litters were used for a chronic toxicity/carcinogenicity study at the same dietary levels as the parents.
Fertility, number of young per litter, birth weight, growth rate and mortality during the lactation period were not adversely affected and there were no indications of increased mortality in utero. Growth rate was slightly decreased in the top dose group of the F0 and F1 generations. In the teratogenicity studies, no adverse effects were seen in appearance, food consumption, autopsy of the dams, organ weights, or litter data; no visceral or skeletal abnormalities attributable to the treatment were observed. In the four-week feeding study with the F3b-generation rats body weights and food efficiency figures were slightly decreased in males at the highest dose level. The relative weights of the caecum were slightly increased in both sexes of the high-dose group and in males of the mid-dose group. These findings were considered to represent an adaptive condition. Gross and microscopic examination did not reveal any treatment-related pathological changes. In the teratogenicity studies general appearance, food consumption and autopsy findings, organ weights 'and litter data were not adversely affected at any dose level. Visceral and skeletal examination of fetuses did not reveal any teratogenic effects attributable to the feeding of the test substance. The only effects of the test substance which were considered treatment-related consisted of inconsistent, slight decreases in body weights in the top-dose group, and a slight increase in the weight of the caecum.
Finally, the NOAEL for fertility and reproductive performance was 3.0% (30000 ppm corresponding to about 1500 mg/kg bw/day) a dose level exceeded the current limit dose of 1000 mg/kg bw/day.
Short description of key information:
The NOAEL for fertility and reproductive performance was 3.0% (30000 ppm corresponding to about 1500 mg/kg bw/day) a dose level exceeded the current limit dose of 1000 mg/kg bw/day.
Justification for selection of Effect on fertility via oral route:
Acesulfame potassium was investigated for its effect on fertility, reproductive performance, pre- and postnatal development in male and female Wistar rats in three successive generations, each comprising two consecutive litters. This study is assessed as appropriate and valid since it was performed comparable to an internationally accepted testing guideline with deviations that can be considered as minor. Reporting, assessment and data presentation in the study report was considered as appropriate considering the date of study and report.
Effects on developmental toxicity
Description of key information
Acesulfame potassium administered orally to pregnant rats or rabbits did not lead to any maternal or developmental toxicity and especially to no morphological alterations in the fetuses.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 900 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The quality of the whole data base is considered to be sufficient and not critical.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
The prenatal developmental toxicity of Acesulfame potassium was investigated in pregnant female Wistar rats. Each 20 pregnant females received dietary dose levels of 0, 0.3%, 1.0% and 3.0% from implantation at gestation day (GD) 6 through GD 15 (counting from day 0 of pregnancy). A positive control group received 75000 IU Vitamin A palmitate/day dissolved in soybean oil.
Signs of maternal toxicity did not occur and food consumption and body weight/body weight gain was not adversely affected. Increased food consumption was noted but this can not be considered as adverse effects. The oral administration of the test substance to the dams at all 3 dose levels had no influence on the gestational parameters. Signs of prenatal developmental toxicity including morphological alterations were not observed at any concentration. The mean fetal weights were slightly increased but this can not be considered as adverse effect. The positive control group showed a wide range of known abnormalities and demonstrated the sensitivity of the test system.
Thus, Acesulfame potassium administered to pregnant Wistar rats orally via the diet at 0, 0.3%, 1.0% and 3.0 % from implantation at gestation day (GD) 6 through GD 15 (counting from day 0 of pregnancy) did not lead to any maternal or developmental toxicity and especially to no morphological alterations in the fetuses.
The no observed adverse effects level (NOAEL) for maternal toxicity as well as for developmental toxicity including teratogenicity was 3.0% in the diet (30000 ppm corresponding to about 1500 mg/kg bw/day) and was thus clearly above the current limit dose of 1000 mg/kg bw/day.
The prenatal developmental toxicity of Acesulfame potassium was investigated in pregnant rabbits. Each 12 – 14 pregnant females received the test substance dissolved in re-distilled water at dose levels of 0, 100, 300 and 900 mg/kg bw/day by gavage from implantation at gestation day (GD) 7 through GD 17 (counting from day 0 of pregnancy). The application volume was 5 mL/kg bw and the control group received the vehicle (water) for comparison.
Signs of maternal toxicity did not occur and food consumption and body weight/body weight gain was not adversely affected. The oral administration of the test substance to the dams at all 3 dose levels had no influence on the gestational parameters. Signs of prenatal developmental toxicity including morphological alterations were not observed at any concentration.
Finally, Acesulfame potassium administered to pregnant rabbit orally by gavage at dose levels of 0, 100, 300 and 900 mg/kg bw/day from implantation at gestation day (GD) 7 through GD 19 (counting from day 0 of pregnancy) did not lead to any maternal or developmental toxicity and especially to no morphological alterations in the fetuses.
The no observed adverse effects level (NOAEL) for maternal toxicity as well as for developmental toxicity including teratogenicity was 900 mg/kg bw/day.
Justification for selection of Effect on developmental toxicity: via oral route:
The prenatal developmental toxicity of Acesulfame potassium was investigated in pregnant female rabbits. This study is assessed as appropriate and valid since it was performed similar to internationally accepted testing guideline and reporting, assessment and data presentation in the study report was considered as appropriate.
Justification for classification or non-classification
Acesulfame potassium did not impair reproductive performance including fertility in rats and did not show any developmental toxicity in rats and rabbits up to the highest dose levels tested.
The study results triggers the following classification/labelling:
EU Directive 1999/45/EC (as amended): none
Regulation (EC) No 1272/2008 (CLP): none
GHS (rev. 4) 2011: unclassified
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.